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Background: HIV-infected patients have a known increased risk of kidney disease. 
For that reason, a biomarker that enables reliable detection of early and mild kidney 
dysfunction would be advantageous. Cystatin C is considered to be a better marker 
of kidney function than creatinine.  
Objectives: This study aimed to evaluate if serum cystatin C was a better marker 
than creatinine in a HIV-infected population. 
Material and Methods: This was an observational study of HIV-infected patients that 
attend the Infectious Diseases Department, at the Hospital Santa Maria, Lisbon.  
Patients with known kidney disease or HIV-2 infection were excluded. Clinical and 
demographic data was recorded and serum creatinine and cystatin C levels were 
determined.   
Results: A total of 242 patients were included. Cystatin C is an independent factor of 
age, gender, ethnicity and body mass index. Of the 17 patients with elevated levels 
of cystatin C but with an estimated creatinine clearance within normal range, 11 were 
on antiretroviral therapy with tenofovir and/or atazanavir. Fourteen patients were 
smokers and 10 patients had hepatitis C virus co-infection, which are known causes 
of inflammation.  
In a matched control group of 27 patients, with cystatin C within normal range, the 
majority of patients also were on an antiretroviral regimen with tenofovir and/or 
atazanavir. However, none of them had hepatitis C virus co-infection. Moreover, a 
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statistical association was found between high levels of cystatin C and alanine 
transaminase. 
Differences between biomarkers’ levels and patients on combinations with tenofovir, 
ritonavir boosted atazanavir or both were also studied. Although it was not found any 
statistically significant difference in creatinine and estimated creatinine clearance, 
with cystatin C, patients that were on atazanavir or tenofovir and had a higher level of 
cystatin C, compared with patients that never were on these drugs.  
Conclusion: Cystatin C levels may be increased in inflammatory conditions. 
Therefore, in HIV-infected patients, where chronic systemic inflammation is present, 
often associated to other inflammation sources, such as chronic hepatitis C virus co-
infection, the use of cystatin C to monitor kidney function may overestimate kidney 
impairment. 
In what concerns to nephrotoxicity, it was found that patients on atazanavir had 
higher levels of cystatin C. It is important to develop prospective studies, in order to 












Introdução: Os doentes infectados por VIH possuem um risco aumentado para o 
desenvolvimento de doença renal. Por esta razão, seria importante utilizar um 
marcador que permitisse uma detecção precoce de alterações da função renal. A 
cistatina C tem sido referida na literatura como um melhor marcador da função renal, 
comparativamente com a creatinina. 
Objectivos: O objectivo deste estudo é analisar se a cistatina C sérica constitui um 
melhor marcador da função renal que a creatinina, para a população de doentes 
infectados por VIH. 
Material e métodos: Este é um estudo observacional de doentes infectados por 
VIH, seguidos no Serviço de Doenças Infecciosas do Hospital de Santa Maria, 
Lisboa. Os doentes com doença renal documentada e infecção por VIH-2 foram 
excluídos deste estudo.  
Foram recolhidos dados clínicos e demográficos e foram determinados os níveis 
séricos de creatinina e cistatina C. 
Resultados: Um total de 242 doentes foi incluído neste estudo. Os níveis de 
cistatina C mostraram-se independentes da idade, sexo, etnia e índice de massa 
corporal. Dos 17 doentes com níveis elevados de cistatina C mas com clearance da 
creatinina dentro dos valores de referência, 11 doentes estavam sob terapêutica 
antirretroviral com tenofovir e/ou atazanavir potenciado com ritonavir. Catorze 
doentes eram fumadores e 10 estavam co-infectados por vírus da hepatite C, que 
constitui um factor conhecido de inflamação. Num grupo controlo de 27 doentes, 
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com cistatina C dentro dos valores normais, a maioria dos doentes também se 
encontrava sob terapêutica antirretroviral com tenofovir e/ou atazanavir. No entanto, 
nenhum possuía co-infecção por vírus da hepatite C.  
Foram também analisadas diferenças entre os níveis dos marcadores e doentes em 
combinações com tenofovir, atazanavir potenciado com ritonavir ou com ambos. 
Embora não tenha sido encontrada nenhuma diferença estatisticamente significativa 
nos níveis de creatinina e clearence da creatinina estimado, com a cistatina C, 
doentes sob atazanavir ou tenofovir e atazanavir possuíam níveis mais elevados 
deste marcador, comparativamente com os doentes que nunca estiveram sob estes 
antirretrovirais.  
Conclusão: Os níveis de cistatina C podem aumentar com factores inflamatórios. 
Por esta razão, no caso dos doentes infectados por VIH, onde existe uma 
inflamação sistémica crónica, muitas vezes associada a outras fontes de inflamação, 
como a co-infecção por vírus da hepatite C, a utilização exclusiva da cistatina C para 
a monitorização da função renal pode conduzir a uma sobrestimação de uma lesão 
renal. 
Em termos de nefrotoxicidade, verificou-se que doentes sob atazanavir possuíam 
níveis mais elevados de cistatina C. É de extrema importância, o desenvolvimento 
de novos estudos prospectivos, de forma a permitir a análise do impacto a longo 
prazo destes antirretrovirais mais recentes na função renal. 
 
Palavras-chave: 
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1. Epidemiology of HIV infection 
Human immunodeficiency virus (HIV) infection continues to be an important global 
epidemic, with an estimate of 2.7 million people newly infected and two million 
deceased people due to AIDS related conditions, in the year of 20081.   
 
 
Figure 1- General perspective of HIV infection in the world (1990-2008). 
Number of people living with HIV, number of people newly infected with HIV and 





Nowadays, the number of HIV infected individuals is higher than in any previous 
year, as the advent of the combination antiretroviral therapy (cART) had a dramatic 
impact on morbidity and mortality. In a similar way, the number of AIDS-related 
deaths has declined by over 10% during the last five years1. 
Since the introduction of cART in 1996, developed countries are witnessing changes 
in morbidity and mortality in HIV-infected patients. Opportunistic infections are being 
replaced by kidney, liver and cardiac diseases which are, in developed countries, the 
leading causes of death in this population2 (figure 2). According to the American 
death certificates, that mentioned HIV infection, in the year 2006, kidney disease 
were, in fact, the forth cause of death, only surpassed by pneumonia, liver disease 
and sepis2.   
It is known that a considerable proportion of all HIV-infected patients develop at least 
transient changes in the kidney function, during the course of HIV infection. Studies 
have shown that 20-30% of infected individuals have kidney dysfunctions 3,4, 
whereas others reported that 15% of these patients develop chronic kidney disease 
(CKD) or end-stage kidney disease (ESKD)5. These patients not only have a risk of 
HIV-associated kidney disease, but also an increased risk of other diseases, such as 
thrombotic microangiopathy, associated to the immune system6,7, associated with 
hepatitis virus B or C (HBV/HCV) co-infection8, drug induced nephrotoxicity and 
electrolytic changes. Furthermore, as HIV infection is becoming more frequent in 
older patient groups, age-associated conditions such as diabetes, hypertension or 
metabolic syndrome are now more common. These facts led, in 2005, to the 
publication of guidelines, for Chronic Kidney Disease treatment in HIV-infected 
patients, by the Infectious Diseases Society of America4. 
 
23 
Figure 2- Conditions reported in U.S. death certificates that mentioned HIV 
infection, in 2006. 
Adapted from: Adih et al. JIAPAC 2010 [ahead of print] 







Number of patients 
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2. Mechanism of Kidney Function 
 
The volume of urine excreted per day (around 1.5L) is a result of two opposing 
processes namely, ultrafiltration and reabsorption. In the first process, 180 L or more 
fluid per day is filtered by glomerular capillaries9. The glomeruli filter the blood, 
leaving blood cells and large proteins (such as albumin), while other material, such 
as water, small proteins and waste products are passed through Bowman’s capsule, 
and then into the tubule (figure 3)10.  
On the reabsorption process, more than 99% of this ultrafiltrate is sent back to the 
bloodstream9. Different parts of the tubules perform different functions in this 
process. The proximal convulated tubule processes and reabsorbs the substances 
that are still necessary (water, electrolytes, glucose, amino acids and minerals) 
passing them back to the bloodstream. At the same time that this occurs, other 
substances such as hydrogen ions, ammonia, creatinine and metabolic products of 
drugs are secreted from the bloodstream directly to the tubule10. More water is 
reabsorbed in the distal tubule, which passes the excess water and waste products 
to the collecting tubule, which travels through the ureter and into the bladder10.  
The kidney also secretes hormones namely, erythropoietin, renin, and calcitriol. 
Erythropoietin stimulates the bone marrow to produce new red blood cells (RBCs). 
Renin helps regulate blood pressure, and calcitriol is a form of vitamin D and it is 





















Figure 3- Physiology of a nephron. 
Legend: (1)Filtration; (2)Reabsorption; (3) Secretion; (4) Excretion 
Adapted from: www.cic-caracas.org/departments/science/Topic12.php 
 
 
Although the kidney is a resilient organ, kidney disorders can occur and be either 
glomerular, causing problems in the filtration process, or tubular, affecting the 
reabsorption process, which is often associated with electrolyte imbalances and 
problems in concentrating urine10. The loss of kidney function is usually accompanied 
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by a progressive distortion of kidney morphology and architecture. At an advanced 
stage of the disease, usually called kidney failure, the kidney loses the capacity to 
remove and regulate water and other products and, waste products (causing uremia) 
and excess water (causing swelling) start to build up9. The various kidney diseases 
are categorized according to whether they are acute and potentially reversible or 
chronic and generally irreversible, as well as the site of the damage (either 




3. Acute Kidney Injury  
Acute kidney failure (AKF) is a generic term for an abrupt and sustained decrease of 
kidney function leading to retention of nitrogenous, such as urea and creatinine, and 
non-nitrogenous waste products11.  
Despite the advances in treatment strategies and comprehension of the 
pathogenesis, until recently there was no clear definition of AKF. This definition still 
remains subjected to controversy and there is a lack of consensus. In fact, there are 
more than 30 definitions in the literature for AKF. The definitions varied from a 25% 
increase over baseline serum creatinine to the need for dialysis12.  
The term acute kidney injury (AKI) has been recently proposed to replace AKF, since 
an acute decline in kidney function is generally secondary to an injury which leads to 
functional and structural changes in the kidney13. The term AKI is also intended to 




Figure 4 – RIFLE classification scheme. 
In the risk, injury, fail, loss and end-stage kidney disease (RIFLE) classification the 
criteria (GFR or UO) that lead to the worst possible classification should be used. The 
Failure class is present even if the increase in serum creatinine is below threefold, as 
long as the serum creatinine is 4.0 mg per 100 ml or above in the setting of an acute 
increase of at least 0.5 mg per 100 ml. The shape of the figure indicates that more 
patients (high sensitivity) will be included in the upper category, including some without 
actually having kidney failure (less specificity). In contrast, at the bottom, the criteria are 
strict (high specificity), but some patients will be missed (less sensitivity).  
GFR-glomerular filtration rate; UO-urinary output AKF-acute kidney failure; ESKD-  End-





In order to meet the need of an uniform definition, the Acute Dialysis and Quality 
Initiative (ADQI) group published, in 2004, a new classification which includes several 
parameters: the risk, injury, failure, loss and end-stage kidney disease (RIFLE) 
classification, in which are defined three classes of severity- risk (R), injury (I) and 
failure (F) classes - and two outcomes – loss (L) and end-stage kidney disease 
(ESKD)14.  
The proposed classification of AKI by the RIFLE criteria is shown in figure 4. 
Some studies have applied the RIFLE classification to evaluate the occurrence rate 
and/or outcome of AKI. More recently, this classification has been applied to evaluate 
clinical characteristics and its predictive ability in intensive care unit (ICU) patients, 
one of them specifically directed for critically ill HIV-infected patients15-18. Those 
studies reported a good discriminative ability and in a Portuguese study, Lopes et al. 
reported that the RIFLE criteria represent a helpful tool in the prognosis of ICU HIV-
infected patients18. 
In order to further improve the AKI definition, the Acute Kidney Injury Network (AKIN) 
was created, proposing a modified version of RIFLE classification, known as AKIN 
criteria19. The most important modifications of AKIN criteria include:  
a) the removal of the outcome criteria and the severity criteria are designated 
as stage 1, 2 and 3;  
b) the broadening of the risk category to include an increase in serum 
creatinine of at least 0.3 mg/dl, even if it this does not reach the 50% 
threshold;  
c) the setting of a 48 hour window for the first documentation of any stage;  
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d) the categorization of any patient treated with kidney replacement therapy 
as stage 3 regardless of serum creatinine and urine output. 
The AKIN criteria were found to improve detection of AKI sensitivity when compared 
with the RIFLE classification by Lopes et al .20. On the other hand, a retrospective 
study of the Australian and New Zealand Intensive Care Society database did not 
reveal any significant difference21.  
AKI has been reported in up to 20% of all hospitalized HIV-infected patients22 and 
etiologies of AKI in HIV-infected patients are generally similar to what is seen in non-
infected hospitalized patients23.  
Acute deterioration into kidney failure can be prerenal (hypoperfusion), renal (intrinsic 
to kidney tissue) or postrenal (obstructive) (table 1). 
Prerenal azotemia is characterized by increased levels of nitrogen-containing 
compounds and in the blood caused by a decrease in blood flow to the kidneys, and 
therefore by an insufficient filtering of the blood. This condition is the most common 
cause of AKI in HIV-infected patients24,25. This type of hemodynamic kidney failure 
includes hypovolumetric states, often as a result of gastrointestinal fluid loss, 
associated with profuse vomiting and/or diarrhea. Disordered kidney regulation of salt 
and water balance can also contribute to intravascular volume depletion in these 
patients. Similarly, central or nephrogenic diabetes insipidus in these patients often 
causes unregulated water loss, which leads to dehydration26. Prerenal azotemia can 
also result from sepsis which develops from a combination of endotoxin-associated 
systemic vasodilatation, arterial hypotension, capillary leakage and kidney arteriolar 




Table 1. HIV-related acute kidney diseases.   
Acute Kidney Injury  
Prerenal Prerenal azotemia Hypovolemia (diarrhea, vomiting, bleeding, 
pancreatitis). 
 
Renal ATN Tubular necrosis (pentamidine, aminoglycosides, 
amphotericin B, foscarnet, NSAIDs, contrast 
based dyes, HUS, microangiopathies, 
rhabdomyolisis, statins). 
 
ATIN Interstitial nephritis (cephalosporin, sulfonamides, 
quinolones, phenitoin, beta-lactams, allopurinol, 




Internal obstruction (crystal deposition, tumour 




External obstruction (tumour, prostate 
hyperplasia, urethral obstruction, retroperitoneal 
fibrosis, drug-associated calculi). 
 
ATN- Acute tubular necrosis; ATIN- Acute tubulointerstitial nephritis; NSAIDs- nonsteroidal anti-
inflammatory drugs; HUS- haemolytic uremic syndrome.   
 
 
Acute tubular necrosis (ATN) is the death of tubular cells, when they do not get 
enough oxygen (ischemic ATN) or when they have been exposed to a toxic drug or 
molecule (nephrotoxic ATN). This can be due to hypovolemia, sepsis, shock and use 
of nephrotoxic agents for therapeutic and diagnosis purposes. However, medication-
induced ATN is the most common cause of AKI in hospitalized HIV-infected patients 
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due to the variety of nephrotoxic drugs often required for treatment of opportunistic 
and nosocomial infections27. Commonly implicated drugs include: pentamidine, 
foscanet, amphotericin B, amynoglycoside antibiotics, non-steroid anti-inflammatory 
drugs (NSAIDs). Statin use for hyperlipidemia secondary to cART and concomitant 
use of gemfibrozil have also been found to cause rhabdomyolysis26. 
Acute tubulointerstitial nephritis (ATIN) is an inflammation of the tubules that affect 
the interstitium. ATIN should also be considered as a possible cause of AKI when 
certain drugs are prescribed for HIV-infected patients. Common implicated drugs 
include: β-Lactam antibiotics, sulfonamides, quinolones, phenitoin, allopurinol, 
NSAIDs and indinavir25. 
The deposition of insoluble crystals in the kidney can also cause AKI in HIV-infected 
patients. Severe AKI due to crystal-induced nephropathy can develop in the 
presence of risk factors that increase intra-tubular crystal precipitation. As an 
example, patients with AIDS-associated lymphoma which produce excessive 
amounts of uric acid during cell death24, that cannot be filtered and secreted by the 
kidney, which results in precipitation and deposit of uric acid crystals in the tubular 
lumens of the distal nephron causing intrarenal obstruction24.  Indinavir, sulfadiazine, 
foscarnet and acyclovir have been implicated in crystalluria and intrarenal 
obstruction28. Intravascular volume depletion and low urinary flow rates increase the 
risk for crystal deposition of these substances, as well as uric acid28. 
Abnormal results on urinalysis usually provide the only evidence of crystal-related 
kidney injury. Cristalluria, cylindruria, hematuria and proteinuria in varying degrees 
can be found on urinalysis24,28.  
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Obstruction of the urinary tract is a rare cause of AKI but gains importance in       
HIV-infected patients. Several unusual causes of obstruction have been described in 
these patients23,24, which are summarised in table 1. The most common cause of 
obstruction in HIV-infected patients is the development of drug-induced calculi. This 
has been noted with the antibiotic sulfadiazine and the protease inhibitor indinavir. 
Symptomatic nephrolithiasis, characterized by classic renal colic with hematuria and 
dysuria can also occur28. 
Opportunistic infections and septicaemia are becoming less common causes of 
kidney injury in cART-treated patients. In opposition, drug toxicity is becoming an 




4. Chronic Kidney Disease  
Chronic Kidney Disease (CKD) is a syndrome which results from progressive and 
irreversible destruction of the nephrons, regardless of the cause. It is defined by the 
maintenance of kidney injury or reduced kidney function for three months or longer 
(table 2). Proof of chronicity can be also provided by the demonstration of bilateral 
reduction of kidney size by diagnostic imaging techniques9. Other findings consist 
with long standing kidney disease, such as osteodystrophy, signs of uremia, anemia, 
hyperphosphatemia or hipercalcemia, however these are not specific. In contrast, the 
finding of broad casts in urinary sediments is specific for CKD. The wide diameter of 
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these casts reflects the compensatory function and hypertrophy of surviving 
nephrons9.  
Recently, in a study with 1,239 HIV-infected patients, the CKD prevalence was 
15.5% 29 and in another study it was reported that HIV-infected patients account for 
1-2% of all the end-stage kidney failure population30. 
In Portugal, the annual incidence of HIV-infected patients on dialysis grew from 0.5%, 
in 1997, to 0.9% in 2002. Approximately 75% of these patients were receiving 




Table 2. Stages of chronic kidney disease. 
Stage Description GFR (mL/min/1,73m2) 
I Kidney injury with normal or elevated GFR ≥ 90 
II Kidney injury with a mild GFR reduction 60 – 89 
III Moderate GFR reduction    30 -59 
IV Severe GFR reduction    15 – 29 
V Kidney failure < 15 
 
Chronic kidney disease is defined as kidney injury or GFR<60 mL/min/1.73m2 for more 
than three months. Injury is defined as a pathological alteration or existence of injury 
biomarkers, including changes presented in urinary or imaging exams.    




In cases of CKD in HIV-infected patients, it is important to consider not only infection-
associated etiologies, but also factors or comorbidity conditions which are frequent in 
the general population, such as diabetes mellitus or hypertension. In this group of 
patients, the most frequent cause of CKD is HIV-associated nephropathy (HIVAN).   
HIVAN was first reported in 1984 by Rao et al.32. This author described a focal and 
segmental glomerulosclerosis in nine patients with AIDS and nephritic syndrome. 
Before the cART era, the usual presentation of HIVAN was the onset of 
asymptomatic proteinuria, followed by a rapid decrease of kidney function and, in a 
matter of months, end-stage kidney failure33. It is considered that HIVAN 
pathogenesis involves a direct citotoxic effect, caused by the HIV infection and also 
by viral gene expression in kidney cells. It seems that a host genetic predisposition 
for occurrence of HIVAN might also be present34. Several studies have shown that 
HIVAN is predominant and more severe in black individuals. Nowadays in the USA, 
HIVAN corresponds to the third cause of CKD in the adult black population that 
initiates dialysis 35.   
Non-HIVAN causes of CKD in these patients include: thrombotic microangiopathy, 
HIV immune complex-mediated kidney disease (HIVICK), diabetic nephropathy and 
hypertensive nephropathy (table 3).Thrombotic microangiopathy can occur due to an 
endothelial cell dysfunction, partially mediated by viral proteins36,37. This disease is 
characterized by five findings with variable expression: fever, neurologic dysfunction, 
thrombocytopenia, microangiopathic hemolytic anemia and kidney failure with 
hematuria. Presence of a high level of proteinuria is not frequent, which helps in the 




Table 3. Causes and characteristics of CKD in HIV-infected patients. 
Condition Characteristics 
HIV-associated Nephropathy (HIVAN) 
Severe proteinuria, large echogenic kidneys, 
absent of edema, urinalysis often bland. 
HIV immune complex disease (HIVICK) 
Identical clinical presentation as HIVAN – varying 
degrees of kidney dysfunction. 
Immune complex mediated glomerulonephritis   
Ig A nephritis 
Proteinuria, hematuria, mild kidney dysfunction, 
elevated levels of serum Ig A. 
Post-infectious glomerulonephritis 
Edema, proteinuria, hematuria, hypertension is 
frequent.  
Membranous nephritis 
Sub-epithelial immune deposits (thickened 
glomerular capillary walls), proteinuria, nephrotic 
urine sediment.  
Membranoproliferative glomerulonephritis 
Hematuria with dysmorphic RBCs and casts. 
Proteinuria (50% of patients have nephrotic 
proteinuria). Enlarged kidneys and hypercellular.  
Mesangial proliferative glomerulonephritis 
Edema, hematuria, proteinuria, hyperlipidemia. 
Increase of mesangial cells. 
Fibrillary or immunotactoid glomerulonephritis 
Nephrotic proteinuria, microhematuria, Ig G and 
C3 glomerular deposits.  
Lupus-like nephritis 
Microhematuria, proteinuria, relatively rapid 
progression to kidney failure. Large sub-epithelial 
deposits with a basement membrane reaction. 
Interstitial nephritis 
Proteinuria, hematuria. Kidney biopsy shows 
mononuclear and often eosinophilic cellular 
infiltration of the kidney parenchyma. 
Thrombotic microangiopathies 
Schistocytes on a blood smear (fragmented 
RBCs), thrombocytopenia, lactate dehydrogenase 
level is extremely elevated.  
Minimal change glomerulonephritis 
Severe proteinuria, oval fat bodies can be 
observed, edema, hypoalbuminemia, 
hyperlipidemia, hyponatremia. 
Diabetic nephropathy Persistent proteinuria, microalbuminuria.  
Hypertensive nephropathy 
Hyaline arteriolosclerosis in the kidneys. 
Nephrons with dilated tubules, often hyaline casts 
in the lumen. 




HIVICK represents a variety of different presentations namely, glomerulonephritis 
lupus-like, proliferative, membranous, fibrillar, imunotactoid or post-infection40-43 
(table 3). The pathogenesis of the different forms of HIVICK can have common 
etiologic features, including deposits of immune complexes containing HIV-1 
antigens, specific cytokine expression profiles, genetic factors, inflammatory 
infiltrates, and the development of kidney scarring30. 
Immunoglobulin A (IgA) nephropathy is characterized by mostly IgA deposition in the 
glomerular mesangium and, in HIV-infected patients, appears to be the result of 
immune complexes containing HIV antigens44. It is characterized by proteinuria, 
hematuria, and mild kidney impairment and is less severe than HIVAN and some 
other variants of HIVICK45. Elevated levels of serum IgA, as well as detectable serum 
IgA immune complexes and rheumatoid factor, may be present46. 
IgA nephropathy seems to be more frequent in European men, being quite rare in 
Africa descendents47, as in the non-infected population48. 
Diabetes is one of the leading causes of kidney disease in the general population. In 
Europe and USA, the prevalence of stage 3 CKD, among people with diabetes is 
26.5%49. The pathogenesis of diabetic nephropathy is complex. Initially 
hyperglycaemia, oxidative stress and altered insulin seem to trigger kidney 
vasodilatation, leading to an increase of the glomerular filtration around 25-50% 
above the normal range10. This causes an increased blood pressure and volume 
flowing into the glomeruli, which results in glomerular capillary distension. The 
increased tension and inflammation causes changes to the kidney parenchyma, 
resulting in glomerular and tubular hypertrophy. This leads to a glomerular capillary 
compression, resulting in a decrease of glomerular filtration with microalbuminuria 
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and hypertension10. The progressive increase of cellular damage, including kidney 
podocytes apoptosis, leads to a further decrease on glomerular filtration and the 
occurrence of severe proteinuria (>3g/day). Without intervention, the patient 
eventually progresses to ESKD10.     
Hypertension is another leading cause of CKD. High blood pressure leads to an 
increase of blood volume that passes though the glomeruli, which creates stress on 
the glomerular cells, including mesangial and epithelial cells and podocytes50. This 
leads to an overproduction of vasoactive substances that activate the production of 
inflammatory cytokines and growth factors, which promote cell damage and fibrosis, 
reducing glomerular filtration51. Patients with hypertensive nephropathy usually 
present severe proteinuria, edema and uremia, which can lead to death, frequently 





5. Mechanism of HIV infection of kidney cells 
It is still an issue under discussion whether HIV can or cannot directly infect kidney 
cells. Although viral replication in kidney cells is probably restricted by the lack of 
CD4 and chemokine co-receptors required for viral entry, it was shown that HIV 
transfection allows kidney epithelial cells to produce viral particles52-54.  
The mechanism through which HIV-1 enters kidney cells remains unclear. One 
possibility is viral transcytosis through lymphocytes to kidney epithelial cells55. 
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Another possibility is CCR5 transfer by microparticles released from peripheral blood 
mononuclear cells56.  
The potential role of dendritic cells also needs to be considered. Dendritic cells are 
involved in binding, dissemination and transfer of HIV to lymphoid and non lymphoid 




5. Combination Antiretroviral Therapy 
The first treatment for HIV-infection was available in 1987 and consisted in the 
nucleoside analog reverse transcriptase inhibitor (NRTI) zidovudine (ZDV, Retrovir®, 
first manufactured by GlaxoSmithKline). At the time, most HIV-infected patients were 
dying within months after the diagnosis of AIDS, usually after a sequence of multiple 
episodes of Pneumocystis jiroveci pneumonia57. 
ZDV was initially developed in 1964 as a candidate for cancer chemotherapy, but 
was never used before due to its toxicity57. In initial clinical trials, ZDV monotherapy 
was shown to decrease mortality, increase CD4+ T cell counts and lead to fewer 
opportunistic infections in patients with symptomatic HIV-infection or AIDS58, 59. 
Monotherapy limitations were later demonstrated, as studies showed that the 
duration of ZDV therapy benefits lasted for just one to two years60, 61. However, given 
the prognosis of a patient diagnosed with AIDS at the time, an apparent extension of 
a few months of life was regarded as worthwhile. Nevertheless, this opened a 
window of opportunities for the development of other antiretroviral drugs, with four 
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additional NRTI drugs licensed for this purpose: didanosine (ddI; Videx®, Bristol-
Myers Squibb), zalcacitabine (ddC; Hivid®, Roche), stavudine (d4T; Zerit®, Bristol-
Myers Squibb) and lamivudine (3TC; Epivir®, GlaxoSmithKline).   
Combinations of two NRTI constituted the first cART. Compared to ZDV 
monotherapy, ZDV and ddI62,63, ZDV and 3TC62,63 or ZDV and ddC64 showed to be 
more effective in the increase of CD4+ count and decrease of viral load. 
Two nonnucleoside reverse transcriptase inhibitors (NNRTI) became available 
around 1996, which were, delaviridine (Rescriptor®, Pfizer), which was never 
available in Portugal, and nevirapine (NVP, Viramune®, Boehringer Ingelheim). With 
these new antiretroviral drugs, it was possible to treat HIV-infected patients with three 
drugs. Combination of ZDV, ddI and NVP was found to outperform the efficacy of 
therapy with two nucleosides65, 66. 
Protease inhibitors (PIs), the third class of antiretroviral drugs, were on the market by 
199557. The introduction of PIs represented one of the biggest breakthroughs in HIV 
therapy. Highly active antiretroviral therapy (a term now being substituted by cART), 
that was a combination of a PI and two or three other antiretroviral drugs, help to 
transform HIV infection into a manageable chronic disease for the majority of patients 
with access to these drugs57. 
Nowadays, the situation regarding HIV-infection is completely different from 23 years 
ago. Today there are more than 20 antiretroviral drugs available and life expectancy 
of HIV-infected patients is measured in decades. Because of that, today the weighing 




5.1. cART associated kidney disease 
 
Studies have confirmed a kidney function improvement in HIV-infected patient, when 
cART is initiated67. However as previously mentioned, other studies have already 
associated kidney complications with administration of specific antiretroviral    
drugs68-95 (table 4). 
Indinavir (IDV) (Crixivan®, Merch) seems to be the only PI with significant urinary 
excretion. Nephrolithiasis is known as the most important side effect68 and also 
pyuria associated with progressive loss of kidney function69. Ritonavir (RTV) 
utilization as IDV booster (IDV/r) elevates the risk of nephrolithiasis70 and of 
rhabdomyolysis with possible occurrence of kidney failure71.  
Risk factors of IDV-associated kidney injury include: low body weight, IDV 
administration in doses equal or greater than 1000mg, administration twice a day, co-
administration with cotrimoxazol72 and HCV or HBV co-infection73. 
RTV (Norvir®, Abbot Laboratories) has also been associated with AKI74. Isolated 
cases of nephrolithiasis have also been referenced as associated with administration 
of saquinavir (Invirase® and Fortovase®, Roche)75 and nelfinavir (Viracept®, ViiV 
Healthcare)76. More recently, there was also a published case of AKI associated with 
atazanavir (ATV) (Reyataz®, Bristol-Myers Squibb) administration77.  
Regarding NRTIs, dosages might have to be adjusted in patients with a GFR inferior 
to 60 ml/min/m3, with exception of abacavir that does not need dosage adjustments4.  
Tenofovir disoproxil fumarate (TDF) (Viread®, also present in Truvada®, Gilead 
sciences, and Atripla®, Bristol-Myers Squibb & Gilead Sciences) shares its molecular 
structure with adefovir which utilization is limited by its nephrotoxicity78 
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Table 4. Antiretroviral drug associated kidney injury 
Antiretroviral drug Kidney injury Ref.  








AKI (acute interstitial nephritis) in hypersensitivity reaction 
Fanconi’s syndrome, AKI, lactic acidosis, nephrogenic diabetes 
insipidus 
Kidney tubular acidosis and hypophosphataemia 






















Nucleotide reverse transcriptase inhibitors   
Tenofovir Proximal tubulopathy, nephrogenic diabetis insipidus, AKI [79-83]  












Intratubular precipitation, nephrolithiasis, kidney colic, AKI and CKD 
Not reported 




AKI (in association with ritonavir)  
AKI, pancreatorenal syndrome, rhabdomyolysis 












Fusion inhibitors   
Enfuvirtide Membranoproliferative glomerulonephritis in diabetic patients [97]  






Integrase inhibitors   
Raltegravir Rhabdomyolysis, mild impairment of a pre-existing kidney 
insufficiency, severe AKI 
[98]  












Figure 5 - Proximal tubular cell transport pathway for tenofovir. 
Tenofovir is delivered to the basolateral membrane of proximal tubular cells and is 
transported into the cell by organic anion transporter-1 (OAT-1). Within the cell, 
tenofovir is transported via carrier proteins and is subsequently secreted into the kidney 
tubule by the apical efflux transporters multidrug resistance protein-2 (MRP-2) and 
MRP-4. Disturbances in this secretory pathway (due to increased OAT-1 activity or 
decreased MRP efflux transport activity) may lead to increased tenofovir 
concentrations within the cell, which can cause mitochondrial DNA depletion and 
dysfunction. Ultimately this can cause proximal tubulopathy (AKI or Fanconi 
syndrome).  
NaDC- sodium–dicarboxylate symporter; OCT- organic cation transporter; OAT-1-organic anion 
transporter-1; MRP-multidrug resistance protein; Pgp- P-glycoprotein; TF- Tenofovir; AKI- acute 
kidney injury. 




Although, initial studies did not show high rates of TDF associated with kidney 
failure78 there are already a number of published cases of Fanconi's syndrome post-
TDF administration79-83. This suggests a possibility of specific risk factors in these 
patients. On the other hand, in most of these cases, patients were on TDF and RTV, 
including lopinavir/r, saquinavir/r, amprenavir/r and ATV/r79-83. In fact, 
pharmacokinetics studies demonstrated that an elevation of approximately 32% on 
TDF exposure occurs, when co-administrated with lopinavir/r and 37% when co-
administrated with ATV/r, compared with TDF administration without these PIs83. 
The observation that around 93% of TDF-associated kidney impairment occurred in 
individuals on PIs, have led to the idea that RTV mediated inhibition of the multidrug 
resistance protein 2 (MRP-2) transporter, which mediates TDF excretion into urine in 
the proximal tubule84, may lead to intracellular accumulation of this antiretroviral drug 
(figure 5). For that reason, the higher TDF concentrations could cause proximal 
tubule necrosis. 
Finally, one must not forget that antiretroviral drugs, besides having a direct toxicity, 
have been also associated with several metabolic complications that might lead to 









6. Kidney function assessment: traditional methods versus new 
biomarkers  
Accurate measurement of GFR is costly and time-consuming. Therefore, clinical 
routine monitoring of kidney function is based on urinalysis, proteinuria and/or 
albuminuria determination and, most importantly, it is based on serum creatinine (Cr) 
determination.  
Cr is a by-product from the creatinine phosphate break-down of the muscle 
catabolism and usually is produced at a relatively constant rate. Because there is 
almost no tubular reabsortion of Cr, if the kidney filtration is affected, Cr blood levels 
rise. The normal serum Cr level varies with the technique used to measure it. For an 
adult, the normal range is between 0.6 to 1.2 mg/dl (53 to 106 μmol/L) by the kinetic 
or enzymatic method and 0.8 to 1.5 mg/dl (70 to 133 μmol/L) by the Jaffé reaction99.  
Cr is considered a reliable biomarker of kidney function. However its levels are 
influenced by age, gender, diet type, low body mass, and the presence of hepatic 
disease100-104.  
To overcome some of these limitations, Cr levels are included in formulas that take 
into account other factors such as, age and/or weight, in order to obtain an estimated 
GFR (eGFR) or estimated creatinine clearance (eCrCl).  
The two more commonly used formulae are the Cockcroft-Gault and the simplified 





Nevertheless, these formulas are still not validated for HIV-infected patients. As the 
constant or slow production of Cr makes its rise too small and delayed for early 
detection of a kidney insult, these formulas also have serum Cr limitations. In 
addition, serum Cr concentration can remain relatively stable until approximately 50% 
of kidney function has already been lost105,106. In these cases, kidney function 
changes can be missed if only based on Cr levels. 
Therefore, there remains the need for a reliable biomarker of kidney function that 
allows the detection of mild kidney dysfunction, in order to enable the timely 
diagnosis and intervention in the early stages of a kidney injury. 
 
 
6.1 Cystatin C 
Cystatin C (Cyst C) is a non-glicosilated protein, composed by a single amino acid 
chain, with a molecular weight of 13.3 kDa (figure 6).  















Cyst C functions like a cysteine protease inhibitor and is present in several biologic 
fluids, such as serum or cerebrospinal fluid (CSF).  
Cyst C is not secreted into the tubules and it is not reabsorbed back into the serum. 
Consequently, Cyst C concentration is almost completely dependent of GFR107, 108  
Studies have demonstrated that Cyst C has a strong negative correlation with 
GFR109, 110 and seems to be an earlier87, 111 and superior marker than Cr, for GFR 
estimation112, 113.  Cyst C also appears to be superior to serum Cr in paediatric114-117, 
elderly118 and diabetic patients119-121. On the other hand, the concept of Cyst C being 
independent of body mass has become controversial over the last years108, 122 and 
there are still no standardized methods for Cyst C measurement, nor validated 
formulas for eGFR123-125.  
Figure 6- Ribbon diagram of human cystatin C structure. 
From: Janowski R et al. Nat Struct Biol 2001,8:316-20 
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Other factors mentioned as affecting Cyst C production are: thyroid dysfunction, 
causing a significant decrease in Cyst C levels, as well as high doses of 
corticosteroids that elevates Cyst C expression117, 126. Cyst C serum or plasma levels 
can be determined by two commercial available, fully automated assays: the particle-




6.2 Interleukin 18  
Interleukin 18 (IL-18) is a pro-inflammatory cytokine, synthesized in the proximal 
tubules, as an inactive precursor form of 24 kDa, suffering a later cleavage by 









 Figure 7 – Ribbon diagram of human Interleukin-18 structure. 
From: Kato Z, et al. Nat Struct Biol 2003;10:966-71. 
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This protein is overexpressed in endogenous inflammatory processes, and seems to 
have an important role in host defence against several infections130.  
Pre-clinical trials have indicated that IL-18 mediates acute tubule necrosis in      
mice131, 132 and a posterior study reported an IL-18 sensitivity superior to 99% for AKI 
diagnosis133. In another study, it was shown that IL-18 was an earlier marker of AKI 
in ICU patients, preceding serum Cr elevation in 1-2 days134. The elevation of IL-18 
occurs approximately 12 hours post kidney injury and can be detected by enzyme-
linked immunosorbent assay (ELISA) in urine. 
 
 
6.3 Kidney injury molecule 1  
Kidney Injury molecule 1 (KIM-1) is a 100 kDa transmembranar glycoprotein, with an 







Figure 8 – Ribbon diagram of kidney injury molecule 1 structure. 
From: Santiago C, et al. Immunity 2007:26,299–310. 
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The basal expression of this protein in the kidney is very low, in both rodents and 
humans136,137. Nevertheless, in animal models, KIM-1 is the main induced protein in 
the proximal tubule after a kidney injury, and can be detected in urine. Increase of 
KIM-1 occurs approximately 12 hours post kidney injury137.  
In a recent study performed in mice with different mechanisms of injury in the 
proximal tubule, using histopathology as the reference method, a good performance 
of KIM-1 in nephrotoxicity identification was reported. Moreover, KIM-1 was the 
urinary biomarker with higher sensitivity and specificity from the 21 used in the 
study138. In research, KIM-1 is usually detected by ELISA or microbead. However 
there are still no commercial methods available. 
 
 
6.4 Liver fatty acid binding protein   
Fatty acid binding proteins (FABPs) are small cytoplasmatic proteins of 15 kDa which 
are expressed in all tissues with active metabolism of fatty acids139.  
FABPs function as chaperons, facilitating free fatty acid chains transport from the 
cytoplasmatic membrane to oxidation sites such as the mitochondria or     
peroxissomes139,140.  
Two types of FABPs were identified in the human kidney: a liver-type FABP (L-
FABP) (figure 9), expressed in the proximal tubule and a heart-type FABP (H-FABP), 
















Pre-clinical and clinical trials reported that urinary L-FABP can be a potential 
biomarker for several pathologies, such as CKD, IgA nephropathy, contrast 
nephropathy and diabetic nephropathy142-145. Besides that, clinical studies 
demonstrated that L-FABP has a potential as biomarker for monitoring CKD 
progression. In another study from Kamijio et al. L-FABP increase was shown to be 
proportional to the kidney function deterioration in non-diabetic patients with CKD146. 
A preliminary study from Ferguson et al. suggested L-FABP as an earlier biomarker 
of AKI (compared with serum Cr), specifically in the case of aminoglicosides 
administration147.  
A different study revealed that L-FABP elevation can be detected approximately four 
hours after a kidney injury148. Still, there seems to be some controversy around          
L-FABP specificity. 
Figure 9 – Ribbon diagram of liver fatty acid binding protein structure. 
From: Protein Data Bank 2F72 
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6.5 Lipocalin-2 or Neutrophil gelatinase-associated lipocalin  
Neutrophil gelatinase-associated lipocalin (NGAL) is a protein from the lipocalin 
family with a molecular weight of 25 kDa. It is composed of eight β-strands 
assembled in a β-barrel that encloses a calyx. This calyx binds and transports low 
molecular weight substances149 (figure 10).  
NGAL is expressed by neutrophils and epithelial cells150. Distinct NGAL expression 
levels can be found in different tissues, such as uterus, prostate, lungs, salivary 
glands, trachea, stomach, colon and kidneys151. 
It is known that NGAL binds to siderophores and possibly has an antibacterial 
action152-154. It is thought that this protein can also interact with specific cellular 
receptors, as the cationic transporter 24p3R, extracellular kinases, hepatocyte 
growth factors or the gelatinase B enzyme155-157.   
This protein might also mediate kidney development158, 15 9 and act as a cellular 
growth factor160-162.  
NGAL is one of the most over expressed proteins in the initial stages of AKI. In the 
kidney most of this protein is produced in the Loop of Henle and collecting duct163.  
Studies have shown that NGAL increase can be detected in plasma, serum or urine, 
just two to six hours after the occurrence of kidney injury164 and that this protein 
constitutes a sensitive and specific biomarker of AKI164-166. Moreover it was also 
demonstrated that it has a predictive ability for AKI167, 168 and CKD severity169-177.  
In a large prospective study by Wagener et al .178, it was shown that elevation of 
urinary NGAL (uNGAL) was correlated with cardio pulmonary bypass time and aortic-




























Figure 10 - NGAL crystal structure with the bacterial enterochelin 
ligand. 
 
Bacterial enterochelin is composed of: a) a triserine lactone and b) three 
catecholate groups. These groups, between them, chelate an iron atom or ion. 
Enterochelin complex can be buried in the NGAL calyx, between three positively 
charged amino acids (R81, K125 and K134, where R is arginine and K is lysine). 
 
Adapted from: Fischbach MA, et al. PNAS 2006;103(44):16502-7 
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Several methods have been used for NGAL measurement. Initial studies used 
Western blot assays182, while subsequent studies preferentially used immunoblotting 
and ELISA assays. There are automated commercial methods available, for instance 
Triage® NGAL (Biosite Incorporated, San Diego, USA) or ARCHITECT® (Abbott 




Beside the potential biomarkers mentioned here, there are several others currently in 
study. However, further studies are still necessary in this field, especially in the case 
of HIV-infected patients, where studies of these new biomarkers performances are 





7. Kidney dysfunction frequency in HIV patients of Hospital 
Santa Maria 
Hospital Santa Maria (HSM), Centro Hospitalar Lisboa Norte (CHLN) is one of the 
largest teaching hospitals in the country. It is a 1,300-bed referral tertiary center and 
serves a large proportion of the Lisbon population. Clínica Universitária de Doenças 
Infecciosas (Director: Professor Doutor Franciso Antunes) has a large HIV outpatient 
clinic. Around 3,000 HIV patients are in a regular follow-up, and most are on cART.  
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In a previous study at Clínica Universitária de Doenças Infecciosas, during a 20 
month period (between January 2007 and August 2008), it was shown that 6% 
(n=757) of 12,022 samples from 2,761 HIV-infected patients had a creatinine level 
greater than 1.2 mg/dL (range 1.2-13.5 mg/dL) (unpublished results) (figure 11). 
Using the CKD stages guidelines (Guidelines of HIV Medicine Association of the 
Infectious Diseases Society of America)4 and eGFR, it was found that 4.1% had 
moderate GFR reduction (30-59 mL/min/1.73m2), 0.6% had severe GFR reduction 
(GFR 15-29 mL/min/1,73m2) and 0.7% had kidney failure (GFR<15mL/min/1,73m2) 













Figure 11- Samples distribution per creatinine level. 




Early identification of kidney injury is essential to promote initiation/adjustment of 
cART, suspension of nephrotoxic drugs and control of co-morbid diseases such as 
diabetes and hypertension. Still, to enable this, sensible (early stage detection) and 
specific biomarkers of kidney function that can be associated with disease prognosis, 
are necessary.  
In spite of being influenced by several factors, serum Cr maintains a constant basal 
expression, which makes its rise slowly. 
Furthermore, CKD can be present with minimal or no change in Cr, due to its basal 
reservoir and the raise of Cr tubular secretion. On the other hand, therapeutic 
interventions that would allow the prevention or treatment of AKI must be introduced 
in an early stage, before the rise of serum Cr can be detected181,182. 
Early markers of kidney injury represent the only possibility for an in-time diagnostic 
and intervention, allowing kidney protection from further injuries and from other risk 
factors associated with HIV infection.  
 
The HSM study mentioned above led us to study the kidney function obtained by 
serum Cr in comparison with the one obtained by an apparently promising potential 
biomarker, serum Cyst C, in HIV-infected patients attending the Infectious Diseases 
Department of HSM, CHLN, and evaluate whether this marker could be a better 
alternative than serum Cr for monitoring kidney function in HIV-infected patients 
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I. Cross-sectional observational analysis of kidney function obtained through 
serum Cr and serum Cyst C determinations: 
 
a) Analysis of kidney dysfunction associated risk factors for HIV-infected 
patients; 
b) Determination of kidney dysfunction rate using Cr and eCrCl (patients 
on cART and without treatment); 
c) Determination of kidney dysfunction rate based on serum Cyst C (same 
patient group); 
d) Correlations of Cyst C with Cr, eCrCl and associations with risk factors 
of kidney injury. 
 
 
II. Analysis of differences in kidney function between patients undergoing 
different antiretroviral regimens (with/without TDF, ATV/r). 
 
a) Comparison of serum Cyst C, serum Cr and eCrCl levels between 
patients on cART with TDF, ATV/r and patients on cART that never 
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Material and Methods 
Study settings  
Cross-sectional study with HIV-infected patients who currently attend the HIV 
outpatient clinic, HSM, CHLN.    
Inclusion criteria were: (a) HIV-1 infected patients; (b) age over 18 years; (c) capable 
of having an informed consent. 
Exclusion criteria were: (a) HIV-infected patients with known kidney disease;           
(b) HIV-2 infection. 







The sample size (N) was calculated using the following equation:  
N ≥ [Z 2*[P (1-P)/ (D2)], in which 
 
Z-area under a normal curve corresponding to the desired confidence level (Z0.95); 
P-expected frequency of an event in the population 




Assuming a kidney dysfunction frequency (CrCl<60 mL/min) of 5.4% in this 
population (frequency obtained from the previously mentioned HSM study), the 
inclusion of at least 218 patients as the sample size, will allow both the determination 
of kidney dysfunction frequency and associated risk factors with a confidence level of 
95% (α= 0.05) and a precision of ± 3%. 




Information on age, gender, ethnicity, country of birth medical history and tobacco 
and alcohol use was retrieved.  
Data on risk factors for HIV, duration and history of antiretroviral therapy were also 
assessed. The length of HIV infection was considered as the time since the first 
positive diagnosis. 
CD4+ T cell nadir, current CD4+ T cell count and HIV RNA levels were also 
assessed. 
HBV co-infection was considered positive when the presence of the hepatitis B 
surface antigen (HBsAg) was confirmed. 
HCV co-infection was considered positive for RNA levels equal or higher than         
43 IU/mL (COBAS® Ampliprep/TaqMan® HCV Test, Roche Diagnostics, Amadora, 
Portugal).  
Measurements of alanine transaminase (ALT) and aspartate transaminase (AST) 
were collected in patients with HCV co-infection. 
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Height, weight, blood pressure and fasting glucose measurements were also 
collected. 
Hypertension was defined as systolic blood pressure higher than 140 mmHg, and/or 
diastolic blood pressure greater than 90mmHg and/or use of antihypertensive 
medication.  
Diabetes was defined as fasting glucose levels equal to or higher than 126 mg/dL 
and/or use of antidiabetic medication.  
 
 
Kidney function markers measurements 
Serum Cr level was determined using a modified Jaffé method (ADVIA® 2400 
Chemistry System, Siemens, Portugal).  
CrCl was estimated by the Cockroft-Gault equation:  
eCrCl (mL/min) = [140 - age (years)] x weight (kg) x [0.85 if female] 
/ 72 x serum Cr (mg/dL) 
Increased Cr level was defined as a measurement greater than 1.2 mg/dL. 
Serum Cyst C was determined with a particle-enhanced immunonephelomeric assay 
(N Latex Cystatin C, Dade Behring, Portugal), according to the manufacturer. 





Statistical analysis was performed using the software SPSS version 17.0 (SPSS Inc., 
Chicago, IL, USA).  
Continuous data were summarized as mean (±SD, standard deviation) and median 
(IQR, inter-quartile range) for parametric and non-parametric data respectively, while 
categorical data were represented as proportions. Spearman’s and Pearson 
correlation coefficients were used to evaluate associations between non-parametric 
and parametric variables.  
Pearson’s Chi Square (χ2) and Fisher’s exact test were used to compare categorical 
data, while Student’s t-test and Mann-Whitney U test were used to analyse 
parametric and non-parametric data respectively.  
A multiple linear regression was also performed using age, gender, ethnicity, BMI as 
predictor variables and log transformed cystatin C as the dependent variable.  
Differences, associations and regression coefficients between variables were 
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Demographic and laboratory description of the sample population 
After the application of inclusion and exclusion criteria, 242 HIV-1 infected patients 
were enrolled in this study (table 5). Most of them were Portuguese (85%; n=205) 
and around a seventh of the patients (15%; n=37) were born in foreign countries, 
mainly Portuguese speaking countries (Angola, Cape Verde, Mozambique, Brazil, 
Guinea-Bissau), as well as in the United Kingdom, Switzerland and Zaire.  
HIV infection was acquired, in most cases, by the sexual route (n=189), followed by 
intravenous drug use (n=52), and blood transfusion (n=1).   
Seventy percent of patients were male (n=169), and 90% were Caucasian (n=218). 
The median age of the participants was 45 years old (range: 22-83 years; IQR=14). 
BMI was 24 Kg/m2 (median; range: 16-33 Kg/m2; IQR=5.9). Hypertension was 
present in 58 patients (24%) and diabetes in 27 patients (11%). Forty nine percent of 
the patients (n=119) were current smokers and 7% (n=17) had a documented history 
of alcohol abuse (table 5). 
Overall, patients were infected for a median of 14 years (range 1-25 years, IQR=7). 
Median CD4+ T cell nadir was 216/mm3 (IQR=267), median CD4+ T cell count, at the 
time of the study, was 686/mm3 (IQR=509). From the patients on cART, most had 
viral-RNA levels lower than 40 copies/mL (95%; n=214). 
 




Table 5. Demographic and laboratory data of the study population (n=242) 
Parameter  
Gender (n, %) 
            Male 
            Female 
 
169   (70%) 
73     (30%) 
Age (years) 45     (14) 
Ethnicity (n, %) 
             Caucasian 
              Black 
 
218    (90%) 
24      (10%) 
BMI (Kg/m2) 24      (6) 
Hypertension (n, %) 58      (24%) 
Diabetes (n, %) 27      (11%) 
Current smoking (n, %)    119    (49%) 
Alcohol abuse (n, %) 17      (7%) 
Years of infection 14      (7) 
Years on cART 12      (6) 
On cART (n, %) 225    (93%) 
 HIV RNA>40copies/mL (n, %) 
Treatment failure 
Treatment naïve 
Treatment interruption  
28      (12%) 
11      (5%) 
7        (3%) 
10      (4%) 
CD4+ nadir (cell/mm3) 216    (267) 
CD4+ count (cell/mm3) 686    (509) 
HBV co-infection (n, %) 5        (2%) 
HCV co-infection (n, %) 63      (26%) 
Data are presented as mean (standard deviation) and median (inter-quartile range) 
for parametric and non-parametric data and proportions (n, %) for categorical 
variables. BMI- body mass index; HBV- hepatitis B virus; HCV- hepatitis C virus; Cr- 
creatinine; eCrCl- estimated creatinine clearance; Cyst C- cystatin C 
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Most patients were on antiretroviral treatment (n=225, 93%), of which 5% (n=11) had 
documented treatment failure. From those patients that were not on cART, seven 
(3%) were treatment naïve patients and 10 (4%) had interrupted treatment (due to 
patients’ own decision, a case of lupus and a case of lipodystrophy). 
Among patients on antiretroviral treatment, the median duration of cART was 12 




Table 6. Current cART regimens on 225 HIV-infected patients. 
NRTI 
N(t)RTI 




X  X   65 (29%) 
X X X   61 (27%) 
X   X  36 (16%) 
X X  X  55 (24%) 
X   X X 2 (1%) 
 X  X X 2 (1%) 
  X X X 4 (2%) 
NRTI- nucleoside reverse transcriptase inhibitors; N(t)RTI- nucleotide reverse transcriptase inhibitor; 
NNRTI- non-nucleoside reverse transcriptase inhibitor; TDF-tenofovir disoproxil fumarate; ATV-






Regarding current cART regimens on the 225 patients studied, it was possible to see 
that several antiretroviral combinations were used (table 6). Most patients were on a 
combination that included two NRTI and one NNRT (n=126). In almost half of those 
(61/126) TDF was part of the combination. On the group of patients that were on a 
combination that included PIs (n=99), 52 were on ATV/r. Among the ones that were 
on TDF, 34 were also on ATV/r. 
Regarding HCV and HBV co-infections, 26% (n=63) patients had detectable HCV 
RNA levels and 2% (n=5) had a positive HBsAg determination. Also, one patient was           
co-infected with both HCV and HBV. Among patients with HCV co-infection, the HIV 




Kidney function determination based on serum Cr and Cyst C 
Overall, serum Cr level (median) was 0.84 mg/dL (range: 0.3-1.7 mg/dL; IQR=0.29), 
mean CrCl, estimated by Cockroft-Gault equation, was 102.5 mL/min (mean, ±30.04) 
and, for serum Cyst C levels, the median was 0.72 mg/L (range: 0.43-1.42 mg/L; 
IQR=0.18). 
These biomarkers were also compared between patients on antiretroviral therapy 
(with or without TDF and ATV/r) and naïve patients (table 7). Regarding patients 
without cART, median serum Cr was 0.84 mg/dL (IQR=0.17), mean eCrCl was 100.5 
mL/min (SD ±34) and median serum Cyst C was 0.71mg/L (IQR=0.26). Among 
patients on cART, median serum Cr was 0.85 mg/dL (IQR=0.28), mean eCrCl was 
102.7 mL/min (SD ±19) and mean serum Cyst C was 0.72 mg/L (IQR=0.18). 
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Concerning patients on TDF and ATV/r, simultaneously, only Cyst C levels appeared 
to be higher for cART with ATV/r and TDF+ATV/r when compared to the overall 
group of patients on cART (table 7). 
 
 
Table 7. Kidney function according to the type of antiretroviral therapy. 





Cr  0.84(0.29) 0.85(0.28) 0.85(0.22) 0.90(0.25) 0.89(0.25) 0.84(0.17) 
eCrCl 102.5(±30) 102.7(±19) 102.9(±29) 102(±18) 95.1(±34) 100.5(±34) 
Cyst C 0.72(0.18) 0.72(0.19) 0.73 (0.16) 0.85(0.20) 0.82(0.23) 0.71(0.26) 
Data are presented as mean (standard deviation) and median (inter-quartile range) for parametric and 
non-parametric variables. Cr-creatinine (mg/mL); eCrCl-estimated creatinine clearance (mL/min); Cyst 
C-cystatin C (mg/L); cART-combination antiretroviral therapy; TDF-tenofovir disoproxil fumarate; 





Table 8. Kidney function according to the duration of HIV infection. 
Biomarker <5 years 5-10 years  11-15 years  16-20 years >20 years 
Cr  0.85(0.23) 0.87(0.21) 0.86(0.20) 0.86(0.18) 0.88(0.21) 
eCrCl 117(±42) 103(±34) 104(±31) 99(±23) 100(±31) 
Cyst C 0.72(0.17) 0.75(0.16) 0.72(0.20) 0.75(0.21) 0.81(0.15) 
Data are presented as mean (standard deviation) and median (inter-quartile range) for 
parametric and non-parametric variables. Cr-creatinine (mg/mL); eCrCl-estimated creatinine 




When biomarker levels where analyzed, according to the number of years of HIV 
infection, a statistically significant difference between the groups was not found 
(p>0.05) (table 8). When analysis was performed according to the number of years 
on cART, although it was also not found a statistically significant difference between 
serum Cr and eCrCl levels and years on cART (p>0.05), when a comparison was 
done based on serum Cyst, it was found that patients who were on cART for less 
than five years had lower levels of Cyst C, comparing to the patients that were on 
cART for five years or even for longer periods of time (p<0.05) (table 9). 
 
 
Table 9. Kidney function according to the number of years on cART. 
Biomarker <5 years 5-10 years  11-15 years  >16 years 
Cr  0.85(0.25) 0.85(0.19) 0.85(0.3) 0.90(0.22) 
eCrCl 111(±31) 101(±39) 102(±29) 95(±26) 
Cyst C 0.69(0.14) 0.72(0.16) 0.73(0.14) 0.77(0.24) 
Data are presented as mean (standard deviation) and median (inter-quartile 
range) for parametric and non-parametric variables. Cr-creatinine (mg/mL); 
eCrCl-estimated creatinine clearance (mL/min); Cyst C-cystatin C (mg/L). 
 
 
Biomarker levels were also analyzed according to the CD4+ T cell nadir (table 10). 
Using the same three biomarkers, as before, patients with a CD4+ nadir count lower 
than 200 cells/mm3 showed a slightly lower kidney function compared to patients that 
present a CD4+ nadir count higher than 200 cell/mm3. However, differences found 
did not reach a significant level (p>0.05). 
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Table 10. Kidney function according to CD4+ T cell nadir. 









Cr  0.87(0.27) 0.87(0.2) 0.85(0.29) 0.84(0.11) 0.8(0.25) 
eCrCl 97(±29) 102(±34) 104(29) 103(±28) 109(±28) 
Cyst C 0.76(0.25) 0.74(0.31) 0.71(0.17) 0.7(0.16) 0.7(0.18) 
Data are presented as mean (standard deviation) and median (inter-quartile range) for 
parametric and non-parametric variables. Cr-creatinine (mg/mL); eCrCl-estimated 




Overall, ccorrelations between HIV RNA level and serum Cr was ρ=0.082, with eCrCl 
was r2=0.22 and with serum Cyst C level was ρ= 0.085 (p>0.05). Concerning CD4+ T 
cell count, the correlation with serum Cr was ρ=-0.021, with eCrCl was r2=0.101 and 
with serum Cyst C was ρ=-0.106 (p>0.05).  
 
 
Evaluation of Cyst C and associations with risk factors for kidney injury 
In order to study the correlation among the overall results of serum Cyst C levels with 
serum Cr and eCrCl determinations, a Spearmen’s rank correlation coefficient was 
applied. It showed a positive correlation of serum Cyst C and serum Cr as well as 
estimated CrCl (p<0.01) (figure 12). 
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Figure 12 – Correlation between Cr, Cyst C and estimated CrCl. 
Overall Cyst C levels were plotted against Cr and estimated CrCl for each patient. CrCl was 
estimated using the Cockcroft-Gault equation. Correlations were assessed with Spearman’s rank 
correlation coefficient. Correlations were considered significant for a p< 0.01.  
Cr- creatinine; Cyst C- cystatin C; CrCl- creatinine clearance. 
 
 
To evaluate the variance of serum Cyst C with age, gender, ethnicity and BMI a 
multiple linear regression with log transformed Cyst C as the dependent variable was 
performed (table 11). The variance obtained was low (r2=0.079) and did not reach a 
significant proportion (p>0.05). In comparison, for the same parameters, the variance 
with serum Cr (r2=0.523) and with eCrCl (r2=0.178) as the dependent variable, was 
higher and reached a significant proportion (p<0.05). 
Associations among biomarkers and risk factor for kidney injury were also tested. 
Associations between increased Cyst C levels (greater than 0.96 mg/L) with 
hypertension, current smoking and HCV co-infection were found to be statistically 
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significant (p<0.05). In opposition, associations between decreased levels of eCrCl, 
increased serum Cr (higher than 1.2 mg/mL) and the above mentioned risk factors 
did not reach significance (p>0.05). 
 
 








Constant -0.139 ---- 0.225 
Age 0.001 0.111 0.517 
Gender -0.042 -0.231 0.349 
Ethnicity 0.000 0.002 0.994 
BMI 0.001 0.024 0.891 
      r2 =0.079; p=0.553 
Predictor variables are constant, age, gender, ethnicity and BMI and the dependent 
variable is Log transformed cystatin C. 




Patients with discordant biomarkers determinations 
Using serum Cr determinations, 10 patients (4%) were identified as having kidney 
dysfunction (Cr levels were higher than 1.2 mg/mL). From these, five patients were 
black, one had hypertension, one had diabetes, four patients were co-infected with 
HCV and their ages were between 30-77 years old. 
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Using eCrCl, 12 patients (5%) were identified as having kidney dysfunction (levels 
lower than 60 mL/min). When serum Cyst C levels were used, 27 patients (11%) 
were identified as having kidney dysfunction (higher than 0.96 mg/L) (table 12). 
Seventeen patients that had normal eCrCl showed increased levels of Cyst C. All 
these patients were male, six had hypertension, six patients were co-infected with 




Table 12. Results of eCrCl and cystatin C in 242 HIV-infected patients. 
 
 Normal eCrCl Reduced eCrCl Total 
Normal cystatin C 213 2 215 
High cystatin C 17 10 27 
Total 230 12 242 
 
Normal cystatin C is defined by serum levels below or equal to 0.96 mg/L and high 
cystatin C by serum levels higher than 0.96 mg/L. Normal estimated creatinine 
clearance (eCrCl) is defined by levels equal to or higher than 60 mL/min and 






Table 13. Comparison between two subgroups of patients: within normal range and 
elevated cystatin C levels. 
 Cyst C>0,96 mg/L 
eCrCl>60 mL/min 
n=17 















CD4+ T cell count (cells/mm3) 762.88±432.9 919.47±293.47 
HIV RNA level (copies/mL) <40 <40  



























HBV co-infection 0    3 p>0.05 
HCV co-infection 10 0 p<0.05 
Cyst C- cystatin C; eCrCl- estimated creatinine clearance; TDF- tenofovir disoproxil 
fumarate; ATV/r- atazanavir boosted with ritonavir; ART- antiretroviral therapy; HCV- 





Regarding cART on this group (table 12), four patients were on TDF (range 2-5 years 
of TDF), five patients were on ritonavir boosted atazanavir (ATV/r) (range 1-5 years 
of ATV/r) and three patients were on cART with both TDF and ATV/r (5 years).  
The above mentioned results were further analysed and compared to a matched 
control group of 27 patients, who had normal Cyst C levels. These two groups were 
not statistically different in terms of age, time of infection, viral load, or CD4+ T cell 
count (table 13).  
Of note, while ten patients with high Cyst C levels had HCV co-infection, none of 











Figure 13- Box-plot of cystatin C levels in patients with HIV/HCV co-
infection, according with the levels of ALT. 
ALT levels were considered normal when inferior or equal to 38 IU/L (n=21). The 
remaining groups correspond to moderate ALT increase (n=31) and an increase 
over three times the normal upper limit (n=11). 




To test if there was an association between high levels of Cyst C and increased 
levels of alanin transaminase (ALT) and aspartate transaminase (AST), a          
Mann-Whitney U test was performed with Cyst C and different levels (within normal 
range, slightly elevated, and more than threefold the normal range) of ALT and AST, 
in the patient group co-infected with HIV/HCV (figure 13). It was not found a 
statistically significant association between increased levels of AST and high level of 
Cyst C. On the other way, it was found a statistically significant association between 
increased levels ALT and higher levels of Cyst C compared with the group with   




Analysis of kidney function in patients with different antiretroviral regimens  
 
A possible association between high levels of Cyst C, Cr and decreased eCrCl and 
patients currently on cART with TDF and/or ATV was also studied. Patients currently 
on TDF, ATV or both drugs were compared to patients who were also on cART but 
were never on these two antiretroviral drugs.  
Statistically significant (p<0.05) associations were found between high levels of Cyst 
C and cART with ATV/r, as well as cART with TDF and ATV/r (figure 14). However, 
no statistically significant association was found between these antiretroviral drugs 






























Figure 14- Box-plot of Cyst C and eCrCl levels per cART group. 
w/o TDF/ATV- without tenofovir and atazanavir (n=67); TDF- with tenofovir (n=92); ATV/r- with 
atazanavir boosted with ritonavir (n=13); TDF+ATV/r- with tenofovir and atazanavir (n=29).Patients 
with IDV in the past were excluded. Cyst C-cystatin C; eCrCl-estimated creatinine clearance; cART-







Figure 16- Cr, eCrCl and Cyst C determinations per year on cART. 
The dots represent individual measurements and the lines represent the mean value of those 
measurement. The color blue represents patients on tenofovir, red patients on atazanavir and 
green patients on both antiretroviral drugs. Patients with indinavir in the past were excluded from 
the analysis. Cr-creatinine; eCrCl-estimated creatinine clearance; Cyst C-cystatin C 
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Finally, it was studied the kidney function levels of patients on cART with TDF, ATV/r 
and both antiretroviral drugs (figure 15). Using Cr measurements, patients on ATV/r 
appear to have higher levels in the first two years on this drug. For patients on TDF, 
mean Cr levels seemed to remain constant, while for patients on TDF and ATV/r, Cr 
levels appeared to be higher after the first year on these drugs (figure 16). Estimated 
CrCl measurements gave similar results to Cr, with a difference on the group of 
patients on TDF that appeared to have lower mean levels after five years on this 
antiretroviral drug. Regarding Cyst C measurements, for patients on TDF, it 
appeared to demonstrate a constant mild increase over the years. For patients on 
ATV/r, Cyst C levels where higher in the first two years on this drug and also in those 
who where on ATV/r for five or six years. Concerning the patients on TDF and ATV/r, 





















Material and Methods 
Results 









Since the introduction of effective cART, life expectancy of HIV-infected individuals 
has increased dramatically183. With that, conditions such as kidney, cardiac and 
hepatic diseases gained importance as causes of morbidity and mortality among this 
population2.  
As HIV-infected patients have a known increased risk of kidney disease when 
compared to the general population6-8, a reliable biomarker that enables the detection 
of mild kidney dysfunction is essential and much needed. Similarly to what was seen 
with the discovery of troponin I, as an earlier biomarker of myocardial injury, in terms 
of the impact on in-time decision making and institution of therapy, it is also needed 
an earlier biomarker of kidney dysfunction, in order to protect the kidney from further 
injury and prevent the evolution to CKD and end-stage kidney disease. 
Previous studies seem to indicate that serum Cr levels are influenced by factors such 
as body mass, age, gender and ethnicity. The estimation of CrCl or GFR enables the 
reduction of this effect. However, it is still influenced by limitations associated with Cr 
determination.  
In the present study we tested a potentially alternative biomarker, serum Cyst C 
against the biomarker most commonly used in clinical practice (serum Cr) in a 
population of HIV infected patients, followed-up at an Outpatient Clinic, HSM, CHLN. 
Our sample population was mostly composed by Portuguese, Caucasian males of 45 
years old (median), and the majority of patients had acquired the infection through 
the sexual route (78%) or by intravenous drug use (21%). This sample seem to be 
representative of the general Portuguese HIV-positive population since, according 
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with data from the Instituto Nacional de Saúde Dr. Ricardo Jorge, in 2009, 81.4% of 
the HIV-infected individuals were male, 83.3% had ages between 20-49 years, and    
HIV-infection was acquired mainly by the sexual route (homo- and heterosexual: 
72.7%) and intravenous drug use (23.6%)184. 
In our study, patients also had a BMI within normal range (normal range: 19-25 
Kg/m2; median BMI 24 Kg/m2), approximately half of the patients were smokers and 
also 7% had documented history of alcohol abuse. The high rate of smokers was 
expected, since it is known that a large fraction of HIV-patients smoke cigarettes185. 
Comorbidity conditions that constitute risk factors for kidney disease were present, 
such as hypertension and diabetes, in 24% and 11% of patients, respectively. 
According to a study from the Portuguese Cardiology Society, the VALSIM study, the 
Portuguese hypertension prevalence, for the adult population, was 42.6%186 which is 
considerably higher than the levels obtained in our population. This was not expected 
since our sample population was older than this population. In addition, a study from 
the Portuguese Diabetes Society, the PREVADILAB study, which included 5,167 
adults from different regions of the country, showed that 11.7% had diabetes187 which 
is in accordance with our results.  
Hypertension and diabetes constitute important risk factors for kidney disease, 
especially hypertension, since kidney dysfunction can worsening hypertension which, 
as a consequence, can lead to further kidney damage. The number of patients with 
hypertension on our study was inferior to the general population numbers. This 
seems to indicate that this risk factor does not constitute a major cause of kidney 
disease on this population.  
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The patients included in our study had a long length of HIV infection (median 14 
years) and median CD4+ T cell nadir was 216/mm3. It is known that HIV infection 
induces a chronic immune activation and inflammation in patients successfully 
treated with cART, possibly due to residual HIV replication below the level of 
detection of standard plasma HIV RNA assays188. It also seems to be an association 
between inflammation and kidney dysfunction. In a pilot study from Gupta et al .189, 
HIV infected patients with proteinuria had higher urinary levels of two inflammatory 
cytokines (MCP-1 and RANTES) when compared to HIV infected patients without 
proteinuria. With this fact in mind, it was supposed that patients infected for longer 
would have higher kidney dysfunction rates. However, this was not found in our 
study. It should be noted that this study could have missed an eventual association 
since confounding factors are present due to the retrospective characteristics of the 
study. On the other hand, the mentioned study from Gupta et a l. did not fully 
elucidated if the increase on inflammatory biomarkers reflected systemic or intrarenal 
inflammation. In order to truly determine the association of systemic inflammation 
and kidney dysfunction it would be necessary to analyze a representative sample of 
patients with different lengths of untreated infection, which is extremely difficult. 
Nevertheless, the CD4+ T cell nadir can give us some information on this matter, 
assuming that a lower nadir represent longer lengths of infection. In our study, 
although the three biomarkers seemed to indicate a slightly lower kidney function 
with patients with a CD4+ nadir lower than 200/mm3, it was not found a statistically 
significance difference between the biomarkers levels, which is in accordance with 
the previous analysis with the length of infection. These results seem to indicate that 
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the time of exposure to HIV-infection is not the determinant factor on the occurrence 
of kidney dysfunction.      
The median CD4+ T cell was 686/mm3 which is above the levels generally 
associated with HIV-related opportunistic infections (CD4+ T cell count lower than 
500/mm3). Several opportunistic infections, such as, Pneumocystis j irovecii or 
Cytomegalovirus infection, as well as therapies for these infections, can cause kidney 
dysfunction. However nowadays, with the advent of cART, opportunistic infections do 
not constitute an important cause of kidney disease of HIV-infected patients in the 
developed World.  
All patients that were on cART (n=225), with the exception of 11 patients with 
documented treatment failure, had HIV-RNA levels below 40 copies/mL. Since our 
patients had a long length of HIV infection, they also had a long duration of cART 
(mean 12 years). The most used combination of antiretroviral drugs was two NRTI 
and one NNRTI (n=126). This was expected since the two most used combinations 
are two NRTI plus either one NRTI or one ritonavir boosted PI. Clinicians often 
choose the NNRTI efavirenz instead of a PI/r, since it was demonstrated that this 
drug is as effective as the PIs190 and allow the postponement of PI-associated 
toxicity.  
From the overall regimens, 118 patients were currently on TDF and 53 patients on 
ATV/r, of which 34 were on a combination of both drugs. Therefore, these patients 
not only have a potential risk associated with a long duration of infection, but also the 
risk of nephrotoxicity associated with a long course with some antiretroviral drugs. 
Twenty six percent of patients were co-infected with HCV, probably associated with 
previous sharing of drug injection material, since among these patients almost 90% 
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acquired HIV-infection by the intravenous drug use route. This percentage is in 
accordance with European data which estimates that 20-40% of HIV infected patients 
are co-infected by HCV191. Only five patients were co-infected with HBV, mainly due 
to the fact that the majority of our sample population was Portuguese, where the 
vaccine against HBV is present on the vaccination plan since 1994192. 
Concerning the analysis of kidney function through the different strategies, 
comparisons were always performed between serum Cr, estimated CrCl and serum 
Cyst C determination. It was not found any statistically significant difference in the 
biomarkers levels, between patients without treatment and those currently on cART. 
However, we only had seven treatment naïve patients and 10 in treatment 
interruption in our sample population which limits the statistical analysis. In order to 
take conclusions, it would be required a similar number of patients in this group. It 
was also not found any significant difference between the biomarker levels and the 
duration of infection. While when these levels were analyzed per year on cART, 
although it was not found any difference with Cr and eCrCl, with serum Cyst C it was 
found that patients who were on cART for less than five year had lower levels of Cyst 
C when compared with patients that were on cART for more than five years. These 
results seem to indicate that Cyst C may have detected mild kidney function changes 
that the other biomarkers did not detect and, if that so, the length of exposure to 
antiretroviral drugs may have a more important impact on kidney function than the 
years exposed to the HIV-infection. 
Correlations between the HIV-infection status (HIV-RNA levels and CD4+ T cell 
count) and the three biomarkers was low (between 0.021 and 0.22; ±0.7-1.0 – highly 
correlated; ±0.5-0.69- moderately correlated; 0-±0.49- poorly correlated) and did not 
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reach a significant proportion. Although it was already mentioned, in previous 
studies, that Cyst C had a correlation with HIV-RNA levels and CD4+ T cell count, 
this was not found in our study. However, it should be noted that our patient group 
had a long course of antiretroviral therapy, maintaining suppression of viral 
replication. In one study from Mauss et al.193, Cyst C levels correlated negatively with 
CD4+ T cell count and positively with HIV RNA levels in treatment naïve patients, 
while after antiretroviral therapy initiation, serum Cyst C levels decreased. On the 
other hand, it is possible that high HIV RNA plasma levels might also correspond to 
an increased HIV replication in kidney cells, resulting in local inflammation and injury 
with increase of Cyst C levels194,195.  
Correlations of serum Cyst C with Cr and eCrCl were performed in order to study the 
congruence between determinations. Cyst C was positive correlated with both but 
had a higher correlation with eCrCl. 
In our study, as in other published studies113, 114 ,196 age, gender, ethnicity and BMI, 
had no significant influence on Cyst C levels contrary in what was found with serum 
Cr and eCrCl. This fact allows an increase in sensitivity when compared to serum Cr, 
especially in patients with low BMI, where eGFR overestimation occurs when 
assessed with Cr. In fact, studies have demonstrated that Cockroft-Gault and MDRD-
based GFR estimations can produce different results in patients with low BMI or 
during weight changes197. This point raises a special concern in HIV-infected 
patients, where the initiation of antiretroviral therapy might be accompanied of weight 
gain and therefore, these eGFR alterations may be falsely attributed to new drug 
regimens.   
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Kidney dysfunction rates obtained were different, and varied according to the 
biomarker used. While using serum Cr, 4% (n=10) of patients were identified as 
having kidney dysfunction, when eCrCl was used, 5% (n=24) were identified. These 
results are in accordance with the previously mentioned HSM study, where the 
kidney dysfunction rate, calculated with eCrCl, was 5.4%. Cyst C was the biomarker 
that showed higher rates of kidney dysfunction with twice as much patients (n=27), 
then when using eCrCl. Elevated Cyst C levels in normal eGFR settings have been 
previously described as preclinical kidney disease and have been associated with an 
increased risk of CKD, cardiovascular events and eventually death17, 1 98, 1 99. In the 
present study, 7% of patients (n=17) were identified as having preclinical disease, 
according to this concept. The majority of these patients (n=11) were in cART with 
TDF, ATV/r or both antiretroviral drugs (for at least one year), which have been 
occasionally referenced in the literature as causative agents of tubular dysfunction, 
Fanconi’s syndrome and acute interstitial nephritis77, 200,201. Furthermore, in a recent 
study with a large cohort of 6,843 patients, increasing exposure to both antiretroviral 
drugs was associated with a higher incidence of CKD202.  
On the other hand, in our study, 14 out of 17 patients were current smokers and the 
majority had HCV co-infection (n=10). Moreover, this study showed that elevated 
Cyst C levels were associated with current smoking and HCV co-infection besides 
hypertension and diabetes. In comparison to the overall sample population, these 17 
patients were two years older and had one more year of infection (mean) which is not 
statistically significant. However, the smoking (71%) and hypertension (35%) rates 
were considerably higher than the overall population rates (49% and 24% 
respectively). In the matched control group (n=27), with Cyst C levels within normal 
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range, a major fraction of the patients also had cART with TDF, ATV/r or both. 
However, none had HCV co-infection. In addition, a statistically significant 
association was also demonstrated between higher levels of Cyst C and ALT in 
patients co-infected with HCV. 
These facts might indicate that Cyst C could be flagging inflammation rather than 
kidney dysfunction. 
More than two decades ago, Cyst C had already been referenced as a potent 
regulator in inflammatory processes203. Posterior studies have reported increased 
Cyst C levels in patients with several conditions such as autoimmune diseases204, 
asthma205 and cigarette smoking206. Recently, it has been demonstrated that 
elevated Cyst C levels are associated with high concentrations of inflammation 
markers such as, C-reactive protein, tumour necrosis factor-α and Interleukin-6206, 207. 
HCV infection is associated with persistent liver inflammation that can lead to 
progressive fibrosis. In this process, several enzymes including cathepsins (cysteine 
proteinases) have been found to be involved208.  
As cathepsins’ activity is increased in the fibrotic liver209, Cyst C as a specific inhibitor 
of these enzymes should also have increased levels. Actually, two previous studies 
showed that serum Cyst C concentrations were significantly higher in patients with 
hepatic diseases when compared to the control group. Both studies indicated that 
Cyst C may be useful for monitoring progression of liver fibrosis210, 211. 
Regarding the analysis of the kidney function of patients under different cART 
regimens, although no statistically significant association was found with Cr nor with 
eCrCl, elevated Cyst C was associated with cART with ATV/r and TDF+ATV/r. In 
addition, for patients on antiretroviral combinations including either ATV/r, TDF or 
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TDF+ATV/r, kidney function changes were analyzed per years on these antiretroviral 
drugs. Using the three biomarkers, patients on ATV/r appear to have lower kidney 
function in the first two years on this drug, while with TDF, only Cyst C seemed to 
demonstrate a mild gradual decrease on kidney function during the years. Therefore, 
while with ATV/r kidney dysfunctions may emerge earlier, with TDF the decrease of 
kidney function might be gradual and, therefore, be missed by determinations with 
serum Cr and eCrCl. However, because this is a cross-sectional study, it cannot fully 
evaluate the long-term impact of antiretroviral drugs. More studies are necessary to 
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With the increasing life expectancy of HIV-infected patients and the toxicity to which 
they are subjected due to the various drugs, it is well known the increasing 
importance of monitoring kidney function in these patients, as AKI and CKD are 
becoming commoner. Nevertheless, besides serum Cr determination, there are no 
alternative biomarkers to assess early kidney dysfunction, nor there are validated 
formulas for GFR estimation in this population.  
In the last years, Cyst C has been referenced in several studies as a biomarker that 
could replace Cr. However, in the present study, Cyst C levels, although not 
influenced by age, gender, BMI and ethnicity, seemed to be influenced by other 
factors besides kidney function.  
As Cyst C seems to vary with inflammation markers in HIV-infected patients, where a 
chronic systemic inflammation is present and often associated with other 
inflammation sources, such as HCV co-infection, this biomarker might lead to an 
overestimation of kidney impairment. Therefore, caution must be taken when 
analysing kidney function using Cyst C levels alone.  
In this current time of severe cost restrains, another aspect that deserves our 
attention is the fact that serum Cyst C determination is around seven-fold more 
expensive than serum Cr determination. Therefore the practical clinical benefits that 
justify opting for the use of this tool, also need to be further analysed.  
One limitation of this study was not having a reference method for GFR 
determination, such as inulin or 51Cr-EDTA. Still, the aim of this study was to 
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compare two non-invasive kidney function biomarkers – the most widely used 
method in clinical practice (Cr) and the alternative biomarker Cyst C, in the context of 
HIV infection.  
Another limitation was the fact that it was a cross-sectional study. Although it allowed 
us to recognize some advantages and limitations of Cyst C as an alternative marker 
of kidney function, still, to definitively acknowledge the ability of Cyst C to detect mild 
kidney dysfunctions, earlier than Cr, it would be necessary to perform a prospective 
analysis.  
In addition, an initial objective of testing another promising biomarker –NGAL- was 
not fulfilled in-time for this dissertation, due to time constrains.     
In what concerns the nephrotoxicity associated with cART, an association was found 
between increased levels of Cyst C and cART either with ATV/r or with TDF+ATV/r. 
In addition, using Cyst C appears that patients on TDF show a mild kidney function 
decrease over the years. Even though no statistically significant associations were 
found with increased levels of serum Cr nor with decreased eCrCl, or associations 
with cART with TDF, we believe that it is extremely important to continue the 
development of prospective research projects, in order to assess the real long-time 
impact of these antiretroviral drugs on kidney function. Until then, one should take in 
consideration the benefits and risks of prescribing these recent antiretroviral drugs, in 
comparison with those that are available for several years and that clinicians already 
have the knowledge and experience on the possible complications associated with 
their long-term use.  
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Unfortunately, it seems that Cyst C does not completely overcome the limitations 
associated with serum Cr kidney function determination and does not seem to 
constitute the final answer to this problematic.  
It seems crucial to continue the research in this field, focusing in particular on the 
development of potential novel biomarkers that could enable an earlier detection of a 
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